B. Winding

发表

Early Detection of Bone Metastases in a Murine Model Using Fluorescent Human Breast Cancer Cells: Application to the Use of the Bisphosphonate Zoledronic Acid in the Treatment of Osteolytic Lesions

P Delmas, P. Delmas, P. Clézardin, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Measurement of tumor load and distribution in a model of cancer-induced osteolysis: A necessary precaution when testing novel anti-resorptive therapies

J. Delaissé, N. Brünner, B. Winding, 2004, Clinical & Experimental Metastasis.

Estradiol Enhances Osteolytic Lesions in Mice Inoculated with Human Estrogen Receptor-Negative MDA-231 Breast Cancer Cells in vivo

N. Brünner, B. Winding, P. Høegh-Andersen, 2003, Breast Cancer Research and Treatment.

Factors That Stimulate Osteoclast Activity Identification of Breast Cancer Cell Line-derived Paracrine Updated

M. Oursler, T. Spelsberg, B. Winding, 1999 .

Proteinases in bone resorption: obvious and less obvious roles.

M. Karsdal, R. Baron, Z. Werb, 2000, Clinica chimica acta; international journal of clinical chemistry.

Quantification of the collagenolytic activity of isolated osteoclasts by enzyme‐linked immunosorbent assay

J. Delaissé, T. Sato, B. Winding, 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Pituitary adenylyl cyclase‐activating polypeptides and vasoactive intestinal peptide inhibit bone resorption by isolated rabbit osteoclasts

B. Winding, N. Foged, A. Wiltink, 1997, Experimental physiology.

Evidence of a Correlation of Estrogen Receptor Level and Avian Osteoclast Estrogen Responsiveness

M. Oursler, L. Fitzpatrick, B. Winding, 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

J. Dumont, J. Oldenburg, V. Blanchette, 2018, Haemophilia.

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

J. Oldenburg, E. Santagostino, B. Konkle, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study

J. Oldenburg, V. Jiménez‐Yuste, S. Lethagen, 2019, BMJ Open.

Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.

M. Recht, A. Rauch, K. Fischer, 2021, Blood advances.

Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

J. Oldenburg, M. Ozelo, H. Chambost, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study

J. Astermark, S. Lethagen, E. Andersson, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

M. Ozelo, S. Lethagen, K. Pasi, 2018, Research and practice in thrombosis and haemostasis.

Second messengers and ion channels in acetylcholine-induced chloride secretion in hen trachea.

N. Bindslev, B. Winding, H. Winding, 1992, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

Hormone Replacement Including Osteoporosis

H. L. Jørgensen, B. Winding, H. Jørgensen, 1999 .

Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.

M. Oursler, T. Spelsberg, B. Winding, 1999, Cancer research.

Human breast cancer cells induce angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis

M. Jakobsen, M. Oursler, B. Winding, 2000, Journal of Cancer Research and Clinical Oncology.

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.

J. Oldenburg, V. Jiménez‐Yuste, B. Konkle, 2023, The New England journal of medicine.

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results

C. Königs, M. Ozelo, M. Carcao, 2022, Blood.

Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.

Nils Brünner, Claus Holst-Hansen, N. Brünner, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

High use of pain, depression, and anxiety drugs in hemophilia: more than 3000 people with hemophilia in an 11-year Nordic registry study

J. Astermark, S. Lethagen, F. Baghaei, 2023, Research and Practice in Thrombosis and Haemostasis.

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

B. Kerlin, Michael Wang, S. Lethagen, 2016 .